JB Pharma, one of the fastest growing pharmaceutical companies in India, announced its financial results for the second quarter ended 30th September, 2022.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

For the second quarter ended 30th September 2022, the Company recorded revenue of INR 809 crores as compared to INR 593 crores, registering growth of 36%. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 44% to INR 202 crores as compared to INR 140 crores. Profit after Tax stood at INR 111 crores as compared to INR 98 crores registering growth of 13%.

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “We continue to build further on our strong operating performance across business segments in FY 23. Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period. The momentum in our international business continued across markets, with all three of our verticals performing well. The CMO business has once again been the standout performer and we will continue to invest to scale this business.

Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. And this growth, along with productivity improvement and cost optimization initiatives, is creating strong operating leverage which is enabling us to maintain our margins in an inflationary environment with supply chain challenges.

Operating EBITDA is after excluding non-cash ESOP Charge.
 

For the first half of the financial year 2022-23, the company recorded revenue of INR 1594 crores as compared to INR 1199 crores, registering growth of 33%. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 29% to INR 392 crores as compared to INR 303 crores. Profit after Tax was INR 216 crores as compared to INR 217 crores.